加拿大ＩＤＢｉｏｍｅｄｉｃａｌ公司和美国国立变态反应和感染性疾病研究所即将开始一种Ａ型链球菌(ＧＡＳ)疫苗的临床研究 ,这是 2 0年来的首次。在美国 ,每年受ＧＡＳ感染的人数达 2 50 0万 ,但目前市场上还没有针对这种感染的疫苗。研究人员数十年来一直致力于开发这种疫苗 IDBiomedical Canada and the National Institute of Allergy and Infectious Diseases are about to begin a clinical study of a Streptococcus pneumoniae (GAS) vaccine, the first in 20 years. In the United States, there are 25 million people infected with GAS each year, but no vaccine against the infection is currently available on the market. Researchers have been working on the vaccine for decades